Phase II Study of JNJ-90301900 in Combination with Concurrent Chemoradiotherapy in Patients with Locally Advanced Head and Neck Squamous Cell Carcinoma

The primary objective of this study is to evaluate the efficacy of JNJ-90301900 in combination with concurrent chemoradiation therapy for the treatment of locally advanced head and neck squamous cell carcinoma. This investigation aims to determine the therapeutic potential of this combination regimen in improving clinical outcomes for patients with this malignancy. 5

This clinical trial involves 22 participants diagnosed with locally advanced head and neck squamous cell carcinoma. The study population includes both male and female patients. According to the provided age range codes, the subjects belong to specific age cohorts. The sponsor did not provide additional information regarding general health status, selection methods, or lifestyle considerations.

This Phase 3 clinical trial is designed to evaluate the efficacy and safety of JNJ-90301900 in combination with concurrent chemoradiation therapy for the treatment of locally advanced head and neck squamous cell carcinoma. The study methodology involves a controlled design to assess therapeutic outcomes. The sequence of study activities begins with a screening visit to determine eligibility based on predefined criteria. Following enrollment, participants undergo scheduled follow-up visits to monitor clinical progress and safety profiles. The process concludes with an end-of-study visit. The total duration of participant involvement is determined by the clinical course and study protocol requirements. Early termination from the study may occur according to specific clinical conditions or protocol-defined withdrawal criteria.

Efficacy in the treatment of locally advanced head and neck squamous cell carcinoma will be evaluated according to the established clinical trial protocols.